The National Cancer Institute (NCI) awarded a $269,280 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Translational Genomics Research Institute (TGen) to support research on targeting cellular senescence in pancreatic cancer.
The two-year project aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its potential to improve the efficacy of standard-of-care chemotherapy or immune checkpoint inhibitors in preclinical pancreatic cancer models. Specifically, the project will study how SIWA318 treatment affects the tumor microenvironment and assess the antibody's antitumor activity when combined with existing cancer therapies. The goal is to develop a new therapeutic approach that can enhance the effectiveness of current standard-of-care treatments for pancreatic cancer patients.
Generated 3/4/25, 6:28 AM